好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

A Modified Mediterranean Dietary Intervention for Multiple Sclerosis: Results of a Pilot Study
Multiple Sclerosis
P4 - Poster Session 4 (5:30 PM-6:30 PM)
15-066
To assess clinical trial feasibility and explore effects of a modified Mediterranean dietary intervention in MS  

Interest in the role of diet among MS patients is quite high.  At the same time, there is increasing scientific evidence for the importance of dietary factors in MS incidence and disease course. Based on available literature, we developed a rationally-designed dietary intervention (restrictive, modified Mediterranean diet) and conducted a randomized pilot study in women with MS for 6 months.
Participants were randomly assigned to the modified Mediterranean dietary intervention or control arm (educational seminars). The intervention group received training with the study nutritionist and attended monthly meetings to assess and promote adherence. Formal assessments were completed at baseline and 6 months.
We screened 131 patients between December 2016 and October 2017.  Of these, 36 (27.5%) were eligible and willing to commit to the study. 18/18 assigned to the intervention group and 16/18 assigned to the non-intervention group completed the study.  Self-reported adherence was excellent (mean at 6 months= 90.3%).  Additional adherence data utilizing other measures will be reported. 16/18 participants reported some benefit to their overall health and 14/18 reported specific benefits regarding MS symptoms. Mean change on the Neurological Fatigue Index-MS was -2.3±5.3 compared to +2.0±3.1 for controls (p=0.006) and mean change on Multiple Sclerosis Impact Scale-29 after exclusion of one outlier was -5.0±9.3 vs +4.4±11.1 (p=0.01).     
It is feasible to enroll MS patients into a rigorous dietary intervention study requiring significant commitment and randomization and reasonable to expect high adherence to this type of dietary program utilizing educational methods to promote adherence. Preliminarily, this regimen improves fatigue and decreases the impact of MS symptoms. Larger scale clinical trials to assess the role of diet for symptom management and even as a disease-modifier in MS are feasible and warranted.   
Authors/Disclosures
Ilana B. Katz Sand, MD (Corinne Goldsmith Dickinson Center for MS)
PRESENTER 		The institution of Dr. Katz Sand has received research support from National Multiple Sclerosis Society. The institution of Dr. Katz Sand has received research support from Hirschl Foundation. The institution of Dr. Katz Sand has received research support from National Institutes of Health. Dr. Katz Sand has received personal compensation in the range of $500-$4,999 for serving as a Conference presenter with 好色先生.
No disclosure on file
Emma Benn No disclosure on file
No disclosure on file
No disclosure on file
Michelle Fabian, MD, FAAN (Mount Sinai Hospital) Dr. Fabian has nothing to disclose.
Aaron E. Miller, MD, FAAN (Mt Sinai School Of Med) Dr. Miller has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Accordant Health Services (Caremark). Dr. Miller has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Corevitas (formerly known as Corrona). Dr. Miller has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for MAPI=Pharma. Dr. Miller has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Viatris (Mylan). Dr. Miller has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Guidepoint Global. Dr. Miller has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Gerson Lehrman Group. Dr. Miller has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen Idec. Dr. Miller has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Alexion. Dr. Miller has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Amgen (Horizon Therapeutics). Dr. Miller has received personal compensation in the range of $50,000-$99,999 for serving as an Expert Witness for Sterne Kessler. Dr. Miller has received publishing royalties from a publication relating to health care.
No disclosure on file